MG
DXCM icon

Michael Gelband’s DexCom DXCM Stock Holding History

Michael Gelband’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$1.99M – 2048
2020
Q3 		$1.99M Buy
+20,000
New +$2.09M 0.04% 406

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Michael Gelband's DXCM Position: Q2 2026 in Review

Michael Gelband reduced its DexCom (DXCM) stake by 63% in Q2 2026, selling an estimated $13.4M and leaving 116,548 shares worth $7.85M. The position accounts for 0.05% of the portfolio, ranked #362.

Michael Gelband first reported a position in DXCM in Q1 2019 and has held it in 26 quarters since. The position peaked at $58.1M in Q2 2025. 966 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Michael Gelband held 116,548 shares of DexCom worth $7.85M as of Q2 2026.
  • Michael Gelband sold 200,519 DexCom shares in Q2 2026, an estimated $13.4M.
  • DexCom made up 0.05% of Michael Gelband's portfolio in Q2 2026, its #362 holding.
  • Michael Gelband first reported a position in DexCom in Q1 2019 and has held it in 26 quarters since.
  • Michael Gelband's DexCom position peaked at $58.1M in Q2 2025.
  • 966 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.